Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 86.73M P/E - EPS this Y 33.10% Ern Qtrly Grth -
Income -232.03M Forward P/E -8.35 EPS next Y 26.90% 50D Avg Chg 9.00%
Sales 12.68M PEG - EPS past 5Y - 200D Avg Chg 39.00%
Dividend N/A Price/Book 6.24 EPS next 5Y - 52W High Chg -23.00%
Recommedations 1.50 Quick Ratio 10.07 Shares Outstanding 59.97M 52W Low Chg 223.00%
Insider Own 17.08% ROA -15.16% Shares Float 42.89M Beta 1.79
Inst Own 62.61% ROE -154.98% Shares Shorted/Prior 11.24M/8.07M Price 7.10
Gross Margin -171.08% Profit Margin - Avg. Volume 259,943 Target Price 33.25
Oper. Margin -1,977.16% Earnings Date Aug 7 Volume 70,175 Change -2.07%
About Immunome, Inc.

Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.

Immunome, Inc. News
07/19/24 Immunome Insiders Added US$2.67m Of Stock To Their Holdings
06/27/24 Immunome Appoints Phil Tsai as Chief Technical Officer
05/21/24 Insider Buying: Immunome Inc's CEO Acquires 100,000 Shares
05/20/24 Immunome Announces Completion of Purchase of Assets from Atreca
05/17/24 Immunome Announces Promotion of Max Rosett to Chief Financial Officer
05/14/24 Immunome, Inc. (IMNM) Reports Q1 Loss, Misses Revenue Estimates
05/14/24 Immunome Reports First Quarter 2024 Financial Results and Provides Business Update
05/08/24 Immunome to Present at 2024 Bank of America Healthcare Conference
05/02/24 Immunome Appoints Kinney Horn as Chief Business Officer
04/26/24 Analysts Estimate Immunome, Inc. (IMNM) to Report a Decline in Earnings: What to Look Out for
07:26 AM Immunome Appoints Sandra M. Swain to Board of Directors
04/05/24 Immunome to Present Preclinical Data for IM-3050, Its Lead Radioligand Therapy Candidate, at 2024 American Association for Cancer Research (AACR) Annual Meeting
04/04/24 New Strong Sell Stocks for April 4th
03/28/24 Immunome Reports Full Year 2023 Financial Results and Provides Update on Recently Acquired Assets
03/26/24 Immunome Completes Acquisition of AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala
03/26/24 Ayala Pharmaceuticals Announces Completion of Sale of AL102 to Immunome
03/22/24 Immunome, Inc. (NASDAQ:IMNM) surges 7.6%; individual investors who own 42% shares profited along with institutions
03/07/24 Immunome to Participate in the Leerink Partners Global Biopharma Conference
03/01/24 Immunome to Participate in the TD Cowen 44th Annual Healthcare Conference
02/20/24 Immunome Recognizes Ayala Pharmaceuticals’ Announced Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors
IMNM Chatroom

User Image intratio Posted - 52 minutes ago

$IMNM https://www.intratio.com/stock-forecast/IMNM Immunome Inc. Our model has predicted the stock price of this company has a clearly poor short-term setup and will have a very negative trend in the upcoming months

User Image Vic05 Posted - 2 days ago

$IMNM Some 2 million share days like we had in February and this explodes

User Image Jeff9905 Posted - 1 week ago

$IMNM another job posting. Basic brick and mortar lab tech job. Great sign something is up.

User Image vikingforthewin Posted - 1 week ago

$IMNM blowing up soon guys

User Image Elliotwavedave Posted - 1 week ago

$IMNM it’s still cheap penny flippers. Think twice before you sell and buy your Tito’s at Costco.

User Image vikingforthewin Posted - 1 week ago

$IMNM $IWM

User Image Elliotwavedave Posted - 1 week ago

$IMNM stay away bots!!

User Image Jeff9905 Posted - 1 week ago

$IMNM yep. 6 more job postings . 7/10

User Image Snozz Posted - 2 weeks ago

$IMNM Their CTO is posting on LinkedIn that they are looking for people. The fact that these are CMC roles is very indicative of how they see things progressing. Clinical stage pharm shops looking for CMC talent is a very significant leading indicator.

User Image Jeff9905 Posted - 2 weeks ago

$IMNM lots of hiring (postings anyway) and stock inching up on low volume. Very similar to early Seagen. Just saying.

User Image Jeff9905 Posted - 2 weeks ago

$IMNM 3 more job postings today. Anyone know if they are actually filling these openings?

User Image vikingforthewin Posted - 2 weeks ago

$IMNM Clay won’t let us down, long term investment guys🤓

User Image Jeff9905 Posted - 2 weeks ago

$IMNM another dump at close. Company needs to do something other than siphon off sucker's money.

User Image Raging_Bull777 Posted - 2 weeks ago

$IMNM The co-founder and CEO of SGEN is now the CEO of IMNM. Clay Siegall CEO and CMO Bob Lechleider both lead Seattle Genetics (renamed to Seagen) to be acquired by Pfizer. Solid leadership team with great pipeline. Rinse and Repeat!

User Image vikingforthewin Posted - 3 weeks ago

$IMNM will go much higher starting from today

User Image Jeff9905 Posted - 3 weeks ago

$IMNM when is the supposed Clay effect gonna effect.

User Image Fast_Eddie_Felson Posted - 3 weeks ago

$IMNM from 30 to junk quickly

User Image SeekingOctane Posted - 3 weeks ago

$GILD $IMNM $VINC

User Image SeekingOctane Posted - 06/30/24

$VINC Data Tracking well similar to Trodelvy’s (Same chemo warhead SN38) Phase 1, and that spurred $GILD to buy Immunomedics for $21 billion. $IMNM

User Image Durand32 Posted - 06/28/24

$IMNM I'm in Thailand and just woke up and see 8.6 million shares traded today and the share price barely moved. WTF is going on

User Image SeekingOctane Posted - 06/28/24

$IMNM Selling about done - I think it came from Ayala Advaxis leak out.

User Image intratio Posted - 06/27/24

https://www.intratio.com/stock-forecast/IMNM Immunome Inc. Our automated equity analyst foretells that this company s stock price has a clear poor short-term setup and has a dramatic negative long-term outlook $IMNM

User Image oicu8sum2 Posted - 06/27/24

$IMNM Two 5 minute candles wipe out the gains - traders own this stock until news.

User Image oicu8sum2 Posted - 4 weeks ago

$IMNM Anyone else still in from the $20s? This is rough. Every day down ~5% since the CEO bought in. Looking for an entry.

User Image Vic05 Posted - 1 month ago

$IMNM In for 10700 shares

User Image Fast_Eddie_Felson Posted - 1 month ago

$IMNM gets slaughtered on a daily basis. Clay gonna keep buying the diiiip tho?

User Image Elliotwavedave Posted - 1 month ago

$IMNM weak hands. Where are those little pump bots that set it up for this 3 month shorting? They’ll pay harshly.

User Image Jeff9905 Posted - 1 month ago

$IMNM high volume sell off. Something is wrong. Not filling job openings either....

User Image dee71 Posted - 1 month ago

$IMNM if it crosses 13.44 it’s a buy for a short run

User Image Elliotwavedave Posted - 1 month ago

$IMNM all clay needs to do is announce AI platform for immunome and its heads to 50 lol.

Analyst Ratings
Piper Sandler Overweight May 31, 24
JP Morgan Overweight Apr 30, 24
Guggenheim Buy Apr 15, 24
Wedbush Outperform Apr 1, 24
Wedbush Outperform Jan 23, 24
Wedbush Outperform Dec 19, 23
Cantor Fitzgerald Overweight Mar 20, 23
Chardan Capital Buy Mar 17, 23
Cantor Fitzgerald Overweight Oct 29, 21
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
SIEGALL CLAY B President and CEO President and CEO Oct 02 Buy 5.91 169,204 999,996 319,636 10/04/23
Turner Bruce Chief Strategy Offic.. Chief Strategy Officer Oct 02 Buy 5.91 42,300 249,993 42,300 10/04/23
RAPP MICHAEL Director Director Sep 13 Buy 17.92 45,950 823,424 182,780 09/13/21